Topic overview

Start with the big picture

Ezetimibe acts in jejunal enterocytes by selectively inhibiting NPC1L1, reducing cholesterol absorption and the hepatic cholesterol pool. The resulting LDL-C reduction can be useful alone or as an addition to statin therapy when further lowering is needed. Its broader clinical profile includes indications, once-daily administration, glucuronidation and enterohepatic recycling, and generally mild adverse effects. The lesson also addresses situations requiring caution, including hepatic impairment and concomitant medicines such as cyclosporine, bile acid sequestrants, fibrates, and anticoagulants. Clinical evidence, monitoring considerations, and special-population guidance round out the topic.